EGFR, HER2 & Receptor Tyrosine Kinases

Cat. No.

AT1463

CAS No.

947687-12-9

Cixutumumab

Synonyms: IMC-A12; NSC742460

Cixutumumab (IMC-A12) is a human monoclonal antibody targeting the insulin-like growth factor 1 receptor (IGF-1R) with high affinity. It effectively inhibits ligand-dependent activation of the receptor and subsequent downstream signaling pathways. Additionally, Cixutumumab facilitates the internalization and degradation of IGF-1R, contributing to its inhibitory effects. This antibody demonstrates broad-spectrum antitumor activity, making it suitable for research in various cancer types including lung cancer, leukemia, non-small cell lung cancer, and prostate cancer. Cixutumumab is an essential tool for studies exploring the role of the IGF-1R pathway in cancer pathogenesis and therapy.

Cat. No.

AT1472

CAS No.

1310460-85-5

Futuximab

Futuximab is a chimeric monoclonal antibody designed to bind specifically to non-overlapping epitopes on the Epidermal Growth Factor Receptor (EGFR). This targeted binding is intended to inhibit the receptor's activity, thereby exerting antineoplastic effects. Futuximab is employed in research focused on the modulation of EGFR function and its role in cancer pathogenesis.

Cat. No.

AT1480

Anti-c-Kit Antibody (LMJ729)

Synonyms: LOP628 antibody

The Anti-c-Kit Antibody (LMJ729), also known as LOP628 antibody, is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the stem cell factor receptor (SCFR), also recognized as c-Kit or CD117. This antibody has a predicted molecular weight of 150 kDa. For isotype control purposes, the Human IgG1 kappa, Isotype Control is recommended. This antibody is designed for the detailed study of c-Kit expression and function in various research applications.

Cat. No.

AT1484

CAS No.

2254097-05-5

Calotatug

Calotatug is a human monoclonal antibody of the IgG1κ isotype, specifically designed to target ERBB2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control. This antibody is pivotal in studies focused on the role of ERBB2 in various biological processes and diseases.

Cat. No.

AT1488

CAS No.

2981438-63-3

Ruzaltatug

Ruzaltatug is a humanized IgG1 monoclonal antibody engineered to specifically target ERBB3, also known as HER3. This receptor is a critical component of the EGFR family, known for its role in promoting tumor growth and conferring resistance to targeted cancer therapies. By binding to ERBB3, Ruzaltatug effectively inhibits key downstream signaling pathways, including PI3K/AKT, thereby potentially reducing cancer cell proliferation and enhancing cell death. Additionally, as a humanized IgG1 antibody, Ruzaltatug is capable of mediating antibody-dependent cellular cytotoxicity (ADCC), adding a mechanism that may contribute to its therapeutic efficacy. Recommended isotype controls for this antibody are Human IgG1 kappa, Isotype Control, to ensure accurate experimental results.

Cat. No.

AT1496

Anti-ERBB1/EGFR/HER1 Antibody (7A7)

Cat. No.

AT1498

CAS No.

1174900-84-5

Ficlatuzumab

Ficlatuzumab is a monoclonal antibody specifically designed to target human hepatocyte growth factor (HGF). This antibody effectively blocks the activation of the HGF/c-Met signaling pathway, crucial in modulating processes such as cell proliferation, migration, and invasion associated with cancer progression. By inhibiting the c-Met receptor-mediated activities, Ficlatuzumab serves as a potent therapeutic agent in the study and potential treatment of various cancers characterized by overactivation of this pathway.

Cat. No.

AT1521

CAS No.

1512559-37-3

Elgemtumab

Synonyms: LJM716

Elgemtumab (LJM716) is a fully human IgG monoclonal antibody designed to selectively target and bind to human epidermal growth factor receptor 3 (HER3). By binding to HER3, Elgemtumab effectively blocks both ligand-dependent and independent signal transduction pathways, thereby inhibiting cellular proliferation. This targeted mechanism demonstrates significant potential in anti-tumor therapies, making it a valuable tool for oncological research and therapeutic development.

Cat. No.

AT1538

CAS No.

2485779-13-1

Zilovertamab

Synonyms: UC-961; Cirmtuzumab

Zilovertamab (UC-961) is a humanized monoclonal antibody specifically targeting ROR1. It effectively inhibits Wnt5a-induced ROR1 signaling, a pathway implicated in various oncogenic processes. This antibody serves as a critical tool for research into the role of ROR1 in cancer biology and potential therapeutic interventions.

Cat. No.

AT1565

CAS No.

2460400-28-4

Mecbotamab

Synonyms: BA301

Mecbotamab is a humanized IgG1-κ monoclonal antibody specifically designed to target the AXL receptor tyrosine kinase (AXL). This antibody functions as a conditionally active biologic (CAB), allowing for site-specific activation. Mecbotamab can be conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) through a cleavable linker, creating the antibody-drug conjugate (ADC) known as Mecbotamab vedotin (BA3011). This conjugation enhances its potential for targeted cancer therapy by enabling the selective delivery of the cytotoxic drug to AXL-expressing tumor cells, thereby minimizing systemic toxicity.

Cat. No.

B22003

CAS No.

3075939-11-3

Ladarutatug

Ladarutatug is a humanized monoclonal antibody that specifically targets the Tyrosine-protein kinase receptor UFO. This IgG4κ isotype antibody demonstrates potential inhibitory activity on UFO signaling pathways, making it a valuable tool for investigating the implications of UFO in various biological processes. Ladarutatug can be utilized in research applications focused on cancer biology and cellular signaling mechanisms.

Cat. No.

B22014

CAS No.

3058433-18-1

Dulpatatug

Dulpatatug is a monoclonal antibody that specifically targets the ERBB2 receptor, playing a key role in cellular signaling pathways associated with various cancers. It exhibits significant potential in research applications, particularly for gastric cancer, breast cancer, and non-small cell lung cancer. This antibody facilitates the exploration of ERBB2's involvement in tumorigenesis and therapeutic resistance, making it a valuable tool for cancer research.